Base de dados : MEDLINE
Pesquisa : D04.210.500.745.745.654.105 [Categoria DeCS]
Referências encontradas : 4030 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 403 ir para página                         

  1 / 4030 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Texto completo
[PMID]:29320647
[Au] Autor:Bassler D; Shinwell ES; Hallman M; Jarreau PH; Plavka R; Carnielli V; Meisner C; Engel C; Koch A; Kreutzer K; van den Anker JN; Schwab M; Halliday HL; Poets CF; Neonatal European Study of Inhaled Steroids Trial Group
[Ad] Endereço:From the Department of Neonatology, University Hospital Zurich, University of Zurich, Zurich (D.B.), and the Division of Pediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital, Basel (J.N.A.) - both in Switzerland; Ziv Medical Center, Faculty of Medicine in the Galilee,
[Ti] Título:Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia.
[So] Source:N Engl J Med;378(2):148-157, 2018 01 11.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The long-term effects on neurodevelopment of the use of inhaled glucocorticoids in extremely preterm infants for the prevention or treatment of bronchopulmonary dysplasia are uncertain. METHODS: We randomly assigned 863 infants (gestational age, 23 weeks 0 days to 27 weeks 6 days) to receive early (within 24 hours after birth) inhaled budesonide or placebo. The prespecified secondary long-term outcome was neurodevelopmental disability among survivors, defined as a composite of cerebral palsy, cognitive delay (a Mental Development Index score of <85 [1 SD below the mean of 100] on the Bayley Scales of Infant Development, Second Edition, with higher scores on the scale indicating better performance), deafness, or blindness at a corrected age of 18 to 22 months. RESULTS: Adequate data on the prespecified composite long-term outcome were available for 629 infants. Of these infants, 148 (48.1%) of 308 infants assigned to budesonide had neurodevelopmental disability, as compared with 165 (51.4%) of 321 infants assigned to placebo (relative risk, adjusted for gestational age, 0.93; 95% confidence interval [CI], 0.80 to 1.09; P=0.40). There was no significant difference in any of the individual components of the prespecified outcome. There were more deaths in the budesonide group than in the placebo group (82 [19.9%] of 413 infants vs. 58 [14.5%] of 400 infants for whom vital status was available; relative risk, 1.37; 95% CI, 1.01 to 1.86; P=0.04). CONCLUSIONS: Among surviving extremely preterm infants, the rate of neurodevelopmental disability at 2 years did not differ significantly between infants who received early inhaled budesonide for the prevention of bronchopulmonary dysplasia and those who received placebo, but the mortality rate was higher among those who received budesonide. (Funded by the European Union and Chiesi Farmaceutici; ClinicalTrials.gov number, NCT01035190 .).
[Mh] Termos MeSH primário: Displasia Broncopulmonar/prevenção & controle
Budesonida/administração & dosagem
Deficiências do Desenvolvimento/epidemiologia
Glucocorticoides/administração & dosagem
Lactente Extremamente Prematuro
[Mh] Termos MeSH secundário: Administração por Inalação
Cegueira/epidemiologia
Paralisia Cerebral/epidemiologia
Transtornos Cognitivos/epidemiologia
Feminino
Seguimentos
Idade Gestacional
Perda Auditiva/epidemiologia
Seres Humanos
Recém-Nascido
Doenças do Prematuro/mortalidade
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Glucocorticoids); 51333-22-3 (Budesonide)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180111
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMoa1708831


  2 / 4030 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29365382
[Au] Autor:Chen QP; Zhou RF; Zhang YM; Yang L
[Ad] Endereço:Department of Paediatrics, Taizhou People's Hospital, Taizhou 225300, China.
[Ti] Título:[Efficacy of systemic glucocorticoids combined with inhaled steroid on children with acute laryngitis].
[So] Source:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi;53(1):53-56, 2018 Jan 07.
[Is] ISSN:1673-0860
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To evaluate the efficacy of systemic glucocorticoid (steroid) combined with high dose inhaled steroid in the treatment of children with acute laryngitis. A total of 78 children with acute laryngitis were randomly divided into study group( =40) and control group( =38) between November 2016 and April 2017. In addition to routine treatment of anti infection and symptomatic treatment, Dexamethasone injection(0.3-0.5 mg/kg, 1-3 d, according to the patient's condition) was provided to each group. In addition to the treatment mentioned above, the study group were assigned to receive 1.0 mg Budesonide suspension for inhalation, oxygen-driven atomizing inhalation, every/30 minutes, 2 times in a row, after that every 12 hours. The improvement of inspiratory dyspnea, hoarseness, barking cough and wheezing of both groups was evaluated at 30 min, 1 h, 2 h, 6 h, 12 h, 24 h and 72 h after treatment.Sigmaplot 11.5 software was used to analyze the data. No significant difference was detected in terms of inspiratory dyspnea, hoarseness, barking cough or stridor score before treatment between the two groups( >0.05). Compared with those before treatment, symptoms of inspiratory dyspnea, hoarseness, barking cough and stridor score of both groups improved markedly at 12 h and 24 h after treatment( <0.05). While there was no significant difference regarding inspiratory dyspnea, hoarseness, barking cough or stridor score at each time point after treatment between the two groups( >0.05). The effective rate was 92.50% and 92.11% in study group and control group, respectively, and no significant difference was noted ( >0.05). Compared with single systemic glucocorticoid, systemic glucocorticoids combined with inhaled steroid possessed similar efficacy in treating acute laryngitis and relieving laryngeal obstruction of children.
[Mh] Termos MeSH primário: Budesonida/uso terapêutico
Dexametasona/uso terapêutico
Glucocorticoides/uso terapêutico
Laringite/tratamento farmacológico
[Mh] Termos MeSH secundário: Doença Aguda
Administração por Inalação
Budesonida/administração & dosagem
Criança
Tosse/tratamento farmacológico
Dexametasona/administração & dosagem
Esquema de Medicação
Dispneia/tratamento farmacológico
Glucocorticoides/administração & dosagem
Rouquidão/tratamento farmacológico
Seres Humanos
Nebulizadores e Vaporizadores
Sons Respiratórios/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Glucocorticoids); 51333-22-3 (Budesonide); 7S5I7G3JQL (Dexamethasone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.1673-0860.2018.01.012


  3 / 4030 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29199436
[Au] Autor:Nagy J; Sági B; Máté J; Vas T; Kovács T
[Ad] Endereço:Klinikai Központ, II. Belgyógyászati Klinika és Nefrológiai Centrum, Pécsi Tudományegyetem, Általános Orvostudományi Kar Pécs, Pacsirta u. 1., 7624.
[Ti] Título:[Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN)].
[Ti] Título:Terápiás megfontolások IgA-nephropathiában a legutolsó vizsgálatok (STOP-IgAN, TESTING, NEFIGAN) eredményei alapján..
[So] Source:Orv Hetil;158(49):1946-1952, 2017 Dec.
[Is] ISSN:0030-6002
[Cp] País de publicação:Hungary
[La] Idioma:hun
[Ab] Resumo:IgA nephropathy is an immune-mediated chronic glomerulonephritis with a great variability in clinical presentation and outcome. The disease can progress to end-stage renal failure in 25% of patients. For this reason we should identify patients with potential to progress. Most important risk factors for progression are persistent proteinuria, hypertension, decreased renal function and some histological lesions. The actually suggested treatment is summarized in KDIGO Clinical Practice Guideline from 2012. They suggest to give firstly non-specific supportive treatment (especially renin-angiotensin system blocking agents). Recommendation about steroid/immunosuppression treatment is based on low level of evidence. Recently three studies were organised concerning benefits and risk of steroid/immunosuppressive treatment added together with specific supportive treatment. In the STOP-IgAN study, systemic steroid/immunosuppressive treatment significantly decreased proteinuria but did not stop progression. In the TESTING study, systemic steroid treatment significantly decreased proteinuria and progression. However, the study was recently discontinued due to several severe side effects of steroid treatment. Involvement of intestinal mucosal immunity in the pathogenesis of IgA nephropathy suggested the NEFIGAN study with budesonide treatment. Budesonide releases corticosteroid in distal small intestine and colon. Proteinuria was significantly decreased and renal function remained stabile. High number of withdrawals owing to adverse effects is a major concern implying a substantial systemic effect of budesonide. We need further information on the characteristics of patients who most likely benefit from steroid/immunosuppressive treatment given after or together with specific supportive treatment. Orv Hetil. 2017; 158(49): 1946-1952.
[Mh] Termos MeSH primário: Glomerulonefrite por IGA/tratamento farmacológico
Imunossupressores/uso terapêutico
Falência Renal Crônica/prevenção & controle
[Mh] Termos MeSH secundário: Budesonida/efeitos adversos
Budesonida/uso terapêutico
Procedimentos Clínicos
Taxa de Filtração Glomerular
Glomerulonefrite por IGA/imunologia
Seres Humanos
Imunossupressão
Falência Renal Crônica/tratamento farmacológico
Proteinúria/tratamento farmacológico
Proteinúria/imunologia
Medição de Risco
Esteroides/efeitos adversos
Esteroides/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunosuppressive Agents); 0 (Steroids); 51333-22-3 (Budesonide)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE
[do] DOI:10.1556/650.2017.30924


  4 / 4030 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29078843
[Au] Autor:Lin X; Fan Y; Wang X; Chi M; Li X; Zhang X; Sun D
[Ad] Endereço:Department of Nursing, Tianjin Medical College, Tianjin, China.
[Ti] Título:Correlation Between Tumor Necrosis Factor-α and Interleukin-1ß in Exhaled Breath Condensate and Pulmonary Function.
[So] Source:Am J Med Sci;354(4):388-394, 2017 Oct.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Exhaled breath condensate (EBC) has emerged as a noninvasive method for assessing inflammation in lung diseases. Our aim is to investigate the correlation between tumor necrosis factor α (TNF-α) and interleukin 1ß (IL-1ß) in EBC and in lung tissue, and between these values in EBC with pulmonary function tests in patients with chronic obstructive pulmonary disease (COPD). MATERIALS AND METHODS: To ensure the availability of lung tissue, 60 patients undergoing resection for early lung cancer were divided into 3 groups: a COPD treatment group, a COPD control group and a non-COPD group. Patients in the COPD treatment group received what was termed "lung-protective treatment" including ambroxol, budesonide and ipratropium bromide in addition to chest physiotherapy. Patients underwent pulmonary function testing and EBC collection, and TNF-α and IL-1ß were detected by enzyme-linked immunosorbent assay (ELISA). TNF-α and IL-1ß in lung tissues were evaluated by immunoflorescense. Correlations were analyzed by Pearson correlation coefficients. RESULTS: The TNF-α and IL-1ß levels in EBC were significantly higher in the COPD groups compared with the non-COPD group before surgery (all P < 0.01), and the levels were significantly decreased after lung-protective treatment was received before surgery (all P < 0.01). TNF-α and IL-1ß levels in EBC were significantly decreased in all patients after surgery with lung-protective treatment (P = 0.027, P = 0.004). TNF-α and IL-1ß content in lung tissues was significantly higher in the COPD groups (all P < 0.05), and the histologic analysis showed similar results. Negative correlations between FEV1/FVC and expression of TNF-α and IL-1ß were observed. There was a positive correlation between TNF-α and IL-1ß in lung tissues and in EBC. CONCLUSIONS: TNF-α and IL-1ß in EBC are potential biomarkers for evaluating pulmonary function and inflammation in patients with COPD. Furthermore, lung-protective treatment is effective in reducing inflammation in patients with COPD.
[Mh] Termos MeSH primário: Interleucina-1beta/metabolismo
Doença Pulmonar Obstrutiva Crônica/metabolismo
Fator de Necrose Tumoral alfa/metabolismo
[Mh] Termos MeSH secundário: Idoso
Ambroxol/administração & dosagem
Testes Respiratórios/métodos
Budesonida/administração & dosagem
Ensaio de Imunoadsorção Enzimática
Feminino
Seres Humanos
Ipratrópio/administração & dosagem
Masculino
Meia-Idade
Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico
Estudos Retrospectivos
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (IL1B protein, human); 0 (Interleukin-1beta); 0 (Tumor Necrosis Factor-alpha); 200168S0CL (Ambroxol); 51333-22-3 (Budesonide); GR88G0I6UL (Ipratropium)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171029
[St] Status:MEDLINE


  5 / 4030 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28923796
[Au] Autor:Veilleux O; Lee TC; McDonald EG
[Ad] Endereço:Department of Medicine (Veilleux, Lee, McDonald), McGill University; Clinical Practice Assessment Unit (Lee, McDonald), McGill University Health Centre, Montréal, Que.
[Ti] Título:Rebound adrenal insufficiency after withdrawal of ritonavir in a 65-year-old man using inhaled budesonide.
[So] Source:CMAJ;189(37):E1188-E1191, 2017 09 18.
[Is] ISSN:1488-2329
[Cp] País de publicação:Canada
[La] Idioma:eng
[Mh] Termos MeSH primário: Insuficiência Adrenal/etiologia
Asma/tratamento farmacológico
Budesonida/administração & dosagem
Infecções por HIV/tratamento farmacológico
Ritonavir/uso terapêutico
Suspensão de Tratamento
[Mh] Termos MeSH secundário: Administração por Inalação
Idoso
Asma/complicações
Broncodilatadores/administração & dosagem
Infecções por HIV/complicações
Inibidores da Protease de HIV
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bronchodilator Agents); 0 (HIV Protease Inhibitors); 51333-22-3 (Budesonide); O3J8G9O825 (Ritonavir)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170920
[St] Status:MEDLINE
[do] DOI:10.1503/cmaj.170415


  6 / 4030 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28836266
[Au] Autor:Onland W; Offringa M; van Kaam A
[Ad] Endereço:Department of Neonatology, Emma Children's Hospital AMC, University of Amsterdam, Meibergdreef 9, Amsterdam, Netherlands, 1105 AZ.
[Ti] Título:Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants.
[So] Source:Cochrane Database Syst Rev;8:CD002311, 2017 08 24.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Bronchopulmonary dysplasia (BPD), defined as oxygen dependence at 36 weeks postmenstrual age (PMA), remains an important complication of prematurity. Pulmonary inflammation plays a central role in the pathogenesis of BPD. Attenuating pulmonary inflammation with postnatal systemic corticosteroids reduces the incidence of BPD in preterm infants but may be associated with an increased risk of adverse neurodevelopmental outcomes. Local administration of corticosteroids via inhalation might be an effective and safe alternative. OBJECTIVES: To determine if administration of inhalation corticosteroids after the first week of life until 36 weeks PMA to preterm infants at high risk of developing BPD is effective and safe in reducing the incidence of death and BPD as separate or combined outcomes. SEARCH METHODS: We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL 2017, Issue 4), MEDLINE via PubMed (1966 to 19 May 2017), Embase (1980 to 19 May 2017), and CINAHL (1982 to 19 May 2017). We also searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials and quasi-randomised trials. SELECTION CRITERIA: We included randomised controlled trials comparing inhalation corticosteroids, started ≥ 7 days postnatal age (PNA) but before 36 weeks PMA, to placebo in ventilated and non-ventilated infants at risk of BPD. We excluded trials investigating systemic corticosteroids versus inhalation corticosteroids. DATA COLLECTION AND ANALYSIS: We collected data on participant characteristics, trial methodology, and inhalation regimens. The primary outcome was death or BPD at 36 weeks PMA. Secondary outcomes were the combined outcome death or BPD at 28 days PNA, the seperate outcomes of death and BPD at both 28 days PNA, and at 36 weeks PMA, and short-term respiratory outcomes, such as failure to extubate; total days of mechanical ventilation and oxygen use; and the need for systemic corticosteroids. We contacted the original trialists to verify the validity of extracted data and to provide missing data. We analysed all data using Review Manager 5. When possible, we performed meta-analysis using typical risk ratio (RR) for dichotomous outcomes and weighted mean difference (WMD) for continuous outcomes along with their 95% confidence intervals (CI). We analysed ventilated and non-ventilated participants separately.We used the GRADE approach to assess the quality of the evidence. MAIN RESULTS: We included eight trials randomising 232 preterm infants in this review. Inhalation corticosteroids did not reduce the separate or combined outcomes of death or BPD. The meta-analyses of the studies showed a reduced risk in favor of inhalation steroids regarding failure to extubate at seven days (typical RR (TRR) 0.80, 95% CI 0.66 to 0.98; 5 studies, 79 infants) and at the latest reported time point after treatment onset (TRR 0.60, 95% CI 0.45 to 0.80; 6 studies, 90 infants). However, both analyses showed increased statistical heterogeneity (I statistic 73% and 86%, respectively). Furthermore, inhalation steroids did not impact total duration of mechanical ventilation or oxygen dependency. There was a trend toward a reduction in the use of systemic corticosteroids in infants receiving inhalation corticosteroids (TRR 0.51, 95% CI 0.26 to 1.00; 4 studies, 74 infants; very low-quality evidence). There was a paucity of data on short- and long-term adverse effects. Our results should be interpreted with caution because the total number of randomised participants is relatively small, and most trials differed considerably in participant characteristics, inhalation therapy, and outcome definitions. AUTHORS' CONCLUSIONS: Based on the results of the currently available evidence, inhalation corticosteroids initiated at ≥ 7 days of life for preterm infants at high risk of developing BPD cannot be recommended at this point in time. More and larger randomised, placebo-controlled trials are needed to establish the efficacy and safety of inhalation corticosteroids.
[Mh] Termos MeSH primário: Anti-Inflamatórios/administração & dosagem
Displasia Broncopulmonar/prevenção & controle
Glucocorticoides/administração & dosagem
Pneumonia/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração por Inalação
Beclometasona/administração & dosagem
Displasia Broncopulmonar/etiologia
Budesonida/administração & dosagem
Dexametasona/administração & dosagem
Fluocinolona Acetonida/administração & dosagem
Fluocinolona Acetonida/análogos & derivados
Fluticasona/administração & dosagem
Seres Humanos
Recém-Nascido
Recém-Nascido Prematuro
Pneumonia/complicações
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Glucocorticoids); 0CD5FD6S2M (Fluocinolone Acetonide); 51333-22-3 (Budesonide); 7S5I7G3JQL (Dexamethasone); CUT2W21N7U (Fluticasone); KGZ1SLC28Z (Beclomethasone); QK4DYS664X (flunisolide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170825
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD002311.pub4


  7 / 4030 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28832630
[Au] Autor:Lin YH; Liao XN; Fan LL; Qu YJ; Cheng DY; Shi YH
[Ad] Endereço:Department of Respiratory Medicine, the First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.
[Ti] Título:Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D.
[So] Source:PLoS One;12(8):e0183300, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The systemic inflammation is associated with clinical outcome and mortality in chronic obstructive pulmonary disease (COPD) patients. To investigate the effects of tiotropium (Tio) and/or budesonide/formoterol (Bud/Form) on systemic inflammation biomarkers in stable COPD patients of group D, a randomized, open-label clinical trial was conducted. METHODS: Eligible participants (n = 324) were randomized and received either Tio 18ug once daily (group I), Bud/Form 160/4.5ug twice daily (group II), Bud/Form 320/9ug twice daily (group III), or Tio 18ug once daily with Bud/Form 160/4.5ug twice daily (group IV) for 6 months. Systemic inflammation biomarkers were measured before randomization and during the treatment, including C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-8 (IL-8), serum amyloid A (SAA), tumor necrosis factor-α (TNF-α), fibrinogen (Fib), and white blood cell (WBC). RESULTS: After 6-month treatment, CRP levels in group II, group III and group IV changed by a median (interquartile range) of -1.25 (-3.29, 1.18) mg/L, -1.13 (-2.55, 0.77) mg/L, and -1.56 (-4.64, 0.22) mg/L respectively, all of which with statistical differences compared with group I. In addition, there were no treatment differences in terms of IL-8, SAA, TNF-α, Fib and WBC levels. CONCLUSIONS: A long-term treatment with Bud/Form alone or together with Tio can attenuate circulating CRP levels in COPD patients of group D, compared with Tio alone.
[Mh] Termos MeSH primário: Broncodilatadores/uso terapêutico
Budesonida/uso terapêutico
Proteína C-Reativa/metabolismo
Fumarato de Formoterol/uso terapêutico
Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Biomarcadores/sangue
Feminino
Seres Humanos
Masculino
Meia-Idade
Doença Pulmonar Obstrutiva Crônica/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Biomarkers); 0 (Bronchodilator Agents); 51333-22-3 (Budesonide); 9007-41-4 (C-Reactive Protein); W34SHF8J2K (Formoterol Fumarate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183300


  8 / 4030 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28764781
[Au] Autor:Tang X; Nian H; Li X; Yang Y; Wang X; Xu L; Shi H; Yang X; Liu R
[Ad] Endereço:Beijing Key Lab of TCM Collateral Disease Theory Research, School of Traditional Chinese Medicine, Capital Medical University, No.10 Xitoutiao, Youanmenwai, Fengtai District, Beijing, 100069, China.
[Ti] Título:Effects of the combined extracts of Herba Epimedii and Fructus Ligustrilucidi on airway remodeling in the asthmatic rats with the treatment of budesonide.
[So] Source:BMC Complement Altern Med;17(1):380, 2017 Aug 01.
[Is] ISSN:1472-6882
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Asthma is characterized by chronic airway inflammation, leading to structura1 changes in the airway, collectively termed airway remodeling. Airway remodeling is thought to contribute to airway hyper responsiveness and irreversible airflow limitation. The combination of Herba Epimedii (HE) and Fructus Ligustri Lucidi (FLL) decoction and the systemic administration of glucocorticoids (GC) had a synergistic inhibitory action on airway inflammation in the asthmatic model rats. However, the effects of the combination on airway remodeling have not been studied and compared. In the present study, we investigated the effects of the co-administration of combined extracts of HE and FLL with inhaled GC (budesonide) on airway remodeling in the rat asthmatic model induced by ovalbumin (OVA). METHODS: Male Sprague-Dawley rats were sensitized to intraperitoneal OVA followed by repetitive OVA challenge for 7 weeks. Treatments included extracts of HE and FLL (Extracts for short, 100 mg/kg by gastric perfusion), budesonide (1 mg budesonide suspension in 50 ml sterile physiological saline, 3 rats in an ultrasonic nebulizer by nebulized inhabation with a flow of 1.6 ml/min for 30 min), and co-administration of extracts of HE and FLL with budesonide (Co-administration for short) for 4 weeks. Lung histomorphometry and bronchoalveolar lavage fluid (BALF) cell count were assessed 24 h after the final OVA challenge. Levels of interleukin (IL)-4, IL-5 and IgE were measured by ELISA. Expressions of Collagen I and Collagen III were tested by immunohistology. Expressions of transforming growth factor (TGF) -ß1, TGF-ß2 and Smads mRNA were measured by quantitative real-time PCR. RESULTS: Extracts, budesonide and Co-administration significantly reduced allergen-induced increases in the serum levels of IL-4, IL-5 and IgE, the number of eosinophils in BALF, goblet cell hyperplasia, Collagen III integral optical density (IOD) and the mRNA expression of TGF-ß2 and Smad2. Extracts and Co-administration could depress the IOD level of Collagen I and the positive area of Collagen I and Collagen III. Budesonide and Co-administration significantly alleviated the thickening of airway wall. Only Co-administration significantly decreased collagen deposition according to the morphometry of Masson's-stained lung sections, the thickening of airway smooth muscle layer, the number of lymphocytes in BALF and the mRNA expression of TGF-ß1 and Smad3, and this was associated with a significant increase in levels of Smad7 mRNA. CONCLUSIONS: The findings suggested that the combination of budesonide and the herbal extracts had a better synergistic effect on airway remodeling in OVA-reduced asthma rats than the single use of budesonide.
[Mh] Termos MeSH primário: Remodelação das Vias Aéreas/efeitos dos fármacos
Asma/tratamento farmacológico
Budesonida/uso terapêutico
Medicamentos de Ervas Chinesas/uso terapêutico
Epimedium
Ligustrum
Pulmão/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Anti-Inflamatórios/farmacologia
Anti-Inflamatórios/uso terapêutico
Asma/imunologia
Asma/metabolismo
Asma/patologia
Budesonida/farmacologia
Colágeno/metabolismo
Sinergismo Farmacológico
Medicamentos de Ervas Chinesas/farmacologia
Imunoglobulina E/sangue
Interleucinas/sangue
Leucócitos/metabolismo
Pulmão/metabolismo
Pulmão/patologia
Masculino
Músculo Liso/patologia
Ovalbumina
Fitoterapia
RNA Mensageiro/metabolismo
Ratos Sprague-Dawley
Reação em Cadeia da Polimerase em Tempo Real
Proteínas Smad/genética
Proteínas Smad/metabolismo
Fator de Crescimento Transformador beta/genética
Fator de Crescimento Transformador beta/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Drugs, Chinese Herbal); 0 (Interleukins); 0 (RNA, Messenger); 0 (Smad Proteins); 0 (Transforming Growth Factor beta); 37341-29-0 (Immunoglobulin E); 51333-22-3 (Budesonide); 9006-59-1 (Ovalbumin); 9007-34-5 (Collagen)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170901
[Lr] Data última revisão:
170901
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170803
[St] Status:MEDLINE
[do] DOI:10.1186/s12906-017-1891-0


  9 / 4030 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28731412
[Au] Autor:Shimoda T; Obase Y; Nagasaka Y; Nakano H; Kishikawa R; Iwanaga T
[Ad] Endereço:Clinical Research Center, Fukuoka National Hospital, Fukuoka, Japan.
[Ti] Título:Lung Sound Analysis Is Useful for Monitoring Therapy in Patients With Bronchial Asthma.
[So] Source:J Investig Allergol Clin Immunol;27(4):246-251, 2017.
[Is] ISSN:1018-9068
[Cp] País de publicação:Spain
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND OBJECTIVE: Lung sound analysis (LSA) has been reported to be useful for predicting airway obstruction and inflammation in patients with bronchial asthma. Objectives: We examined whether the exhalation-to-inhalation sound pressure ratio in the middle frequency range (200-400 Hz) (E/I MF) is useful for monitoring therapy in patients with asthma. METHODS: The study population comprised 84 patients with mild to moderate asthma whose LSA data were available before and after 1 year of daily treatment with (budesonide 800 µg). We analyzed whether the E/I MF before and after treatment was associated with the fractional exhaled nitric oxide (FeNO) level, sputum eosinophil percentage, respiratory function, and airway hyperresponsiveness. RESULTS: Prior to treatment with budesonide, the E/I MF was significantly correlated with respiratory function, airway hyperresponsiveness, FeNO, and sputum eosinophil percentage. The cutoff values for the E/I MF to detect the abnormalities of respiratory function, FeNO, and sputum eosinophil percentage were 0.367, 0.358, and 0.363, respectively. With respect to the reference value, the E/I MF improved significantly in patients whose respiratory function and FeNO benefited from therapy with budesonide compared with patients whose respiratory function did not benefit from budesonide (odds ratios of 6.39 and 4.78, respectively). According to the multivariate analysis, patients whose E/I MF did not improve had a longer history of smoking (P=.038), poorer posttreatment respiratory function (P=.028), and higher posttreatment FeNO (P=.0095). CONCLUSIONS: Similar to respiratory function and FeNO, E/I MF based on LSA is a useful indicator for monitoring the efficacy of therapy in asthmatic patients.
[Mh] Termos MeSH primário: Asma/tratamento farmacológico
Budesonida/uso terapêutico
Glucocorticoides/uso terapêutico
Hipersensibilidade Respiratória/tratamento farmacológico
Sons Respiratórios/fisiopatologia
[Mh] Termos MeSH secundário: Administração por Inalação
Adolescente
Adulto
Idoso
Asma/imunologia
Asma/metabolismo
Asma/fisiopatologia
Testes Respiratórios
Eosinófilos/citologia
Feminino
Volume Expiratório Forçado
Seres Humanos
Masculino
Meia-Idade
Análise Multivariada
Óxido Nítrico/metabolismo
Testes de Função Respiratória
Hipersensibilidade Respiratória/imunologia
Hipersensibilidade Respiratória/metabolismo
Hipersensibilidade Respiratória/fisiopatologia
Processamento de Sinais Assistido por Computador
Fumar
Escarro/citologia
Capacidade Vital
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 31C4KY9ESH (Nitric Oxide); 51333-22-3 (Budesonide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170831
[Lr] Data última revisão:
170831
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170722
[St] Status:MEDLINE
[do] DOI:10.18176/jiaci.0132


  10 / 4030 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:28719374
[Au] Autor:Ip K; Carvalho M; Shan A; Banov D
[Ad] Endereço:Professional Compounding Centers of America (PCCA), Houston, Texas. KIp@pccarx.com.
[Ti] Título:Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox).
[So] Source:Int J Pharm Compd;21(4):322-329, 2017 Jul-Aug.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Budesonide is a corticosteroid that has been shown effective in the treatment of eosinophilic esophagitis, but there are currently no commercial medicines to treat this chronic allergic/immune condition, despite its prevalence in the U.S. Therefore, pharmaceutical compounding is the alternative choice to meet the therapeutic need of eosinophilic esophagitis patients. Two budesonide mucoadhesive oral suspensions (1 mg/10 mL and 2 mg/10 mL) were developed using the compounding vehicle MucoLox, a proprietary mucoadhesive polymer blend that promotes mucosal adhesion. The physical and chemical stability of the oral suspensions was tested over a period of 182 days, at room temperature and refrigerated conditions, in order to determine the corresponding beyond-use date. The physical characterization consisted in observing all samples for color/appearance and odor, and testing for pH and density, whereas the chemical characterization consisted in ultra-performance liquid chromatography assay testing. Both oral suspensions were proven physically and chemically stable, and the ultra-performance liquid chromatography method was proven stability indicating. As a result, the beyond-use date of the budesonide 1-mg/10-mL and 2-mg/10-mL mucoadhesive oral suspensions (MucoLox), in amber plastic bottles, is six months at both room temperature and refrigerated conditions.
[Mh] Termos MeSH primário: Budesonida/química
[Mh] Termos MeSH secundário: Administração Oral
Cromatografia Líquida de Alta Pressão
Composição de Medicamentos
Estabilidade de Medicamentos
Veículos Farmacêuticos
Suspensões
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Pharmaceutical Vehicles); 0 (Suspensions); 51333-22-3 (Budesonide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170719
[St] Status:MEDLINE



página 1 de 403 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde